Navigation Links
Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinson's Disease
Date:10/14/2008

NEW YORK, Oct. 14 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research awarded a total of $2 million to five research teams to speed development of effective therapies for the under-addressed cognitive and mood-related symptoms of Parkinson's disease. Patients often report these symptoms, which range from problems with executive function (the ability to formulate, sequence, and execute plans) to dementia; depression, apathy and anxiety; and behavioral issues including problems with impulse control, to be among the most difficult aspects of living with PD.

The funding will support pre-clinical and clinical research projects under the Foundation's Cognitive Deficits and Mood Disorders in Parkinson's Disease initiative, made possible by generous leadership funding from Merck Serono, a division of Merck KGaA, Darmstadt, Germany.

"Clinicians and patients alike report how disabling the cognitive and mood effects of PD can be, yet these symptoms are systematically under-researched and are poorly understood," said Katie Hood, CEO of The Michael J. Fox Foundation. "We are thrilled to have found a like-minded partner in Merck Serono so that we can push this work forward."

Elmar Schnee, President of Merck Serono, said: "Merck Serono recognizes the critical need for new therapies to alleviate PD-related cognitive dysfunction. We are pleased to stand side by side with The Michael J. Fox Foundation in prioritizing and supporting research with potential to help speed development of effective treatments that will allow every patient to live a fuller and more satisfying life."

The development of treatments for cognitive and mood symptoms of Parkinson's has been hindered by a lack of preclinical models to explain these features of the disease; a lack of basic knowledge of the mechanisms that underlie these symptoms; inadequate understanding of the clinical features of these symptoms in PD; and a need for relevant clinica
'/>"/>

SOURCE Michael J. Fox Foundation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinsons Disease Under Rapid Response Innovation Awards 2008
2. Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee
3. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
4. Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinsons Disease
5. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
6. Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
7. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
8. New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinsons Clinical Trials
9. Michael J. Fox Foundation Commits Up to $3 Million for Clinical Trials That Can Improve Treatment of Parkinsons Disease
10. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
11. Alzheimers Foundation of America Survey: Americans With Memory Concerns Fall Short of Talking to Doctors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  The International Trade Commission (ITC) ... (RMD) against BMC Medical. In a notice issued on December ... that ResMed,s patent on its humidifier was invalid. ... "monumental win". "We are very excited with the ITC,s decision ... that we have taken since the very beginning on the ...
(Date:12/24/2014)... and FARMINGTON, Conn. , Dec. ... MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific ... significant unmet medical need and commercial potential, today ... placement of 2,050,000 shares of its common stock ... of its common stock.  Funds under the management ...
(Date:12/24/2014)... , Dec. 23, 2014 Echo ... medical device company focused on skin permeation, continuous ... Scott W. Hollander has been appointed ... Hollander has more than 20 years of experience ... industries, and most recently served as Vice President, ...
Breaking Medicine Technology:ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3
... 2011 Reportlinker.com announces that ... is available in its catalogue: ... Drug Safety Strategies and Risk ... clinical success ...
... FRANCISCO, Calif., Oct. 26, 2011 Onyx Pharmaceuticals, ... results from a Bayer HealthCare Pharmaceuticals Phase 3 ... for the treatment of patients with metastatic colorectal ... standard therapies. The trial met its primary endpoint ...
Cached Medicine Technology:Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 2Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 3Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 4Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 5Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 6Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 7Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 8Phase 3 Trial of Investigational Compound Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival 2Phase 3 Trial of Investigational Compound Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival 3Phase 3 Trial of Investigational Compound Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival 4Phase 3 Trial of Investigational Compound Regorafenib in Metastatic Colorectal Cancer Meets Primary Endpoint of Improving Overall Survival 5
(Date:12/25/2014)... 25, 2014 When head lice hits a ... a frenzy to get rid of it while keeping it ... Coral Gables now have the solution right in their neighborhood: ... location, Lice Troopers provides full spectrum head lice screening and ... area, including Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest ...
(Date:12/25/2014)... -- The risk of burns from fires and cooking ... be extra cautious, an expert says. "Between Thanksgiving ... in patients coming in with burns," said Dr. Steven ... Burn Center of Stony Brook University Hospital in New ... but if not careful, could quickly turn tragic," Sandoval ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... be closing in on a "fountain of youth" drug that ... of older adults, a new study suggests. Seniors received ... drug that targets a genetic signaling pathway linked to aging ... The experimental medication, a version of the ...
(Date:12/25/2014)... “ SmileStix ” was featured on NewsWatch as ... coolest mobile applications on the iOS, Android, and Windows markets. ... conducted the app review and shared with viewers how this ... The old saying goes, “A picture says a thousand words.” ... describe a single image, because each picture holds a unique ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Each year ... and 2 million hospital admissions across the nation (according ... ). The CDC’s National Hospital Ambulatory Medical Care ... a survey conducted in 2010. They estimated that there ... that resulted in a primary diagnosis of broken bone ...
Breaking Medicine News(10 mins):Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Don't Let Burns Mar Your Holidays 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4
... One in eight new moms experience postpartum major depressive disorder ... 80 percent of women experience depressive symptoms postpartum, with one in ... Caused by multiple factors, including stress and hormone changes in the ... blues, to major depression and in rare circumstances, the most severe ...
... CRUZ, CA--The National Institute on Drug Abuse (NIDA) has awarded ... Berman, professor and chair of biomolecular engineering at the Jack ... Cruz. With the new five-year grant, Berman,s group ... August issue of the Journal of Virology . The ...
... Mass., Sept. 9 Echo Therapeutics, Inc. (OTC Bulletin ... Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous ... for transdermal drug delivery, announced today that it has ... 2009 Annual Global Investment Conference. Patrick T. Mooney, ...
... ... and Trademark office for knotless surgery tissue fixation to KFx Medical. , ... San Diego, CA (PRWEB) September 9, 2009 -- ... No. 7,585,311 by the United States Patent and Trademark office. The key patent covers a ...
... , More than 1.3 million Americans ... , , WASHINGTON, Sept. 9 Leading opponents of ... National Center for Policy Analysis (NCPA) and Salem Radio Network delivered the ... Now" petition to Congress at a rally held on Capitol Hill. , ...
... SAN DIEGO, Sept. 9 US Farms, Inc. (Pink ... that it has filed a Trademark Application in the United States, ... http://tarr.uspto.gov/servlet/tarr?regser=serial&entry=77821663 . , , ... a diversified Farming, Nursery and Wellness Company. The company grows, markets ...
Cached Medicine News:Health News:Prentice Women's Hospital Launches New Initiative to Better Identify and Address Postpartum Depression 2Health News:Prentice Women's Hospital Launches New Initiative to Better Identify and Address Postpartum Depression 3Health News:Prentice Women's Hospital Launches New Initiative to Better Identify and Address Postpartum Depression 4Health News:$3.5 million NIH grant supports AIDS vaccine research at UC Santa Cruz 2Health News:$3.5 million NIH grant supports AIDS vaccine research at UC Santa Cruz 3Health News:Echo Therapeutics Announces New Presentation Time at Rodman & Renshaw 2009 Annual Global Investment Conference 2Health News:KFx Medical Awarded Key Patent for Knotless Tissue Fixation and Double Row Rotator Cuff Surgery 2Health News:National Center for Policy Analysis and Salem Radio Network Deliver Million-Plus Signature Petition Opposing Government Run Health Care 2Health News:National Center for Policy Analysis and Salem Radio Network Deliver Million-Plus Signature Petition Opposing Government Run Health Care 3Health News:US Farms, Inc. Files Trademark Application for Aloe365 2
For use with catalog #0540....
Enzyme Immunoassay of D-Dimer by ELISA Method, 96 tests....
Immuno-turbidimetric Assay of D-Dimer by STA© Analyzers. Microlatex particles coated with two different mouse monoclonal anti-human D-Dimer antibodies....
Latex Agglutination Slide Test for the Qualitative and Semi-Quantitative Determination of D-Dimer in plasma, 60 tests....
Medicine Products: